Research led by the CDC and conducted at seven academic pediatric medical centers in the United States finds nirsevimab (sold ...

In a new study, the RSV drug nirsevimab was 93% effective at preventing young children from being hospitalized for the ...

Effectiveness of Nirsevimab for Respiratory Syncytial Virus in Infants and Young Children,” published in the November 2024 ...

FDA advisors said that more data are needed to fully understand if there are broader safety concerns related to use of ...

As the respiratory illness season begins, cases of respiratory syncytial virus (RSV) cases are rising in Canada. But new tools offers hope for prevention.

Most positive tests for RSV so far this season in Canada have been among the youngest, federal data suggests. And while ...

This analysis documented the continued high burden of medically attended respiratory syncytial virus (RSV)-associated acute respiratory illness among young children in the U.S. Nirsevimab and maternal ...

Covid-19 hospitalizations, which typically rise throughout December and peak sometime in January, remain low for now.

This analysis documented the continued high burden of medically attended respiratory syncytial virus (RSV)-associated acute ...

The FDA flagged at least five cases of severe or very severe RSV lower respiratory tract infections in infants immunized with ...